Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
Citations Over TimeTop 10% of 2012 papers
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is an important therapeutic target for the treatment of diseases such as cancer that involve pathological immune escape. Starting from the scaffold of our previously discovered IDO1 inhibitor 4-phenyl-1,2,3-triazole, we used computational structure-based methods to design more potent ligands. This approach yielded highly efficient low molecular weight inhibitors, the most active being of nanomolar potency both in an enzymatic and in a cellular assay, while showing no cellular toxicity and a high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO). A quantitative structure-activity relationship based on the electrostatic ligand-protein interactions in the docked binding modes and on the quantum chemically derived charges of the triazole ring demonstrated a good explanatory power for the observed activities.
Related Papers
- → Induction of Indoleamine 2,3-Dioxygenase In Vivo by IFN-con1(2001)9 cited
- → Pharmacological Inhibition of the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO) Cooperatively Leverages Cytotoxic Chemotherapy(2005)
- → ATP promotes immunosuppressive MSCs inhibiting lymphocyte proliferation and expressing indoleamine dioxygenase(2017)
- Screening of the inhibitory activity of Korea local plant extracts against indoleamine 2,3-dioxygenase (IDO) = 한국 자생식물 추출물의 Indoleamine 2,3-dioxygenase (IDO) 저해활성(2011)
- 教15-2 妊娠免疫とIDO (Indoleamine 2, 3-dioxygenase)(アレルギー疾患の発症における免疫・神経・内分泌系のクロストーク,ミニシンポジウム,教育コース15(基礎・その他),第22回日本アレルギー学会春季臨床大会)(2010)